Anti-Human CD279 Recombinant Antibody(Spartalizumab)
-
产品编号
YR1475
-
别名
科研级 Spartalizumab, Anti-CD279 Recombinant Antibody, Research Grade Spartalizumab
-
规格
- 1mg
- 5mg
产品介绍
| Alias | 科研级 Spartalizumab, Anti-CD279 Recombinant Antibody, Research Grade Spartalizumab |
| Catalog Number | YR1475 |
| Molecular Name | Spartalizumab |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | IgG4 Kappa |
| Formulation | PBS, pH7.5 |
| Background | Spartalizumab (INN, development code PDR001) is a monoclonal antibody that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials. |
| CAS Number | 1935694-88-4 |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Target | CD279[Homo sapiens] |
-
400-621-6806 -
614353794 -
周一至周五 9:00-18:00 -
-
0
-
